Suppr超能文献

ERBB 家族下游途径的动态模拟,包括突变和治疗:与实验结果的一致性。

Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results.

机构信息

Department of Internal Medicine, University of Genoa, Genova, Italy.

出版信息

Curr Cancer Drug Targets. 2010 Nov;10(7):737-57. doi: 10.2174/156800910793605848.

Abstract

The pathways downstream of ErbB-family proteins are very important in BC, especially when considering treatment with onco-protein inhibitors. We studied and implemented dynamic simulations of four downstream pathways and described the fragment of the signaling network we evaluated as a Molecular Interaction Map. Our simulations, enacted using Ordinary Differential Equations, involved 242 modified species and complexes, 279 reversible reactions and 111 catalytic reactions. Mutations within a single pathway tended to be mutually exclusive; only inhibitors acting at, or downstream (not upstream), of a given mutation were active. A double alteration along two distinct pathways required the inhibition of both pathways. We started an analysis of sensitivity/robustness of our network, and we systematically introduced several individual fluctuations of total concentrations of independent molecular species. Only very few cases showed significant sensitivity. We transduced the ErbB2 over-expressing BC line, BT474, with the HRAS (V12) mutant, then treated it with ErbB-family and phosphorylated MEK (MEKPP) inhibitors, Lapatinib and U0126, respectively. Experimental and simulation results were highly concordant, showing statistical significance for both pathways and for two respective endpoints, i.e. phosphorylated active forms of ERK and Akt, p one tailed = .0072 and = .0022, respectively. Working with a complex 39 basic species signaling network region, this technology facilitates both comprehension and effective, efficient and accurate modeling and data interpretation. Dynamic network simulations we performed proved to be both practical and valuable for a posteriori comprehension of biological networks and signaling, thereby greatly facilitating handling, and thus complete exploitation, of biological data.

摘要

表皮生长因子受体(ErbB)家族蛋白下游途径在乳腺癌(BC)中非常重要,特别是在考虑使用致癌蛋白抑制剂治疗时。我们研究并实施了四个下游途径的动态模拟,并将我们评估的信号网络片段描述为分子相互作用图。我们的模拟使用常微分方程执行,涉及 242 个修饰物种和复合物、279 个可逆反应和 111 个催化反应。单个途径内的突变往往是相互排斥的;只有作用于或下游(而非上游)给定突变的抑制剂才是有效的。两个不同途径的双重改变需要抑制两个途径。我们开始分析我们网络的敏感性/鲁棒性,并系统地引入了几个独立分子物种总浓度的单独波动。只有极少数情况表现出显著的敏感性。我们用 HRAS(V12)突变体转导过表达 ErbB2 的 BC 细胞系 BT474,然后分别用 ErbB 家族和磷酸化 MEK(MEKPP)抑制剂拉帕替尼和 U0126 进行处理。实验和模拟结果高度一致,两条途径和两个相应终点(即 ERK 和 Akt 的磷酸化活性形式)均具有统计学意义,p 单侧值分别为.0072 和.0022。使用复杂的 39 个基本物种信号网络区域,这项技术不仅促进了对生物网络和信号的理解,还促进了有效、高效和准确的建模和数据解释。我们进行的动态网络模拟不仅具有实用性,而且对于事后理解生物网络和信号也非常有价值,从而极大地促进了生物数据的处理,进而实现了对其的充分利用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验